KYLE NEWMAN: Open Payments
NPI 1467796185 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$641 in 43 payments from 9 companies in 2025. Trend: 2023 $301 · 2024 $1,248 · 2025 $641
Food & beverage: $641
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 14 | $178 |
| ABBVIE INC. | 14 | $150 |
| Axsome Therapeutics, Inc. | 6 | $147 |
| Neuronetics, Inc. | 2 | $47 |
| Alkermes, Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
Products named: COBENFY, VRAYLAR, Auvelity, NEUROSTAR TMS THERAPY SYSTEM, LYBALVI, ABILIFY ASIMTUFII, INGREZZA, AUSTEDO XR.
Industry payments across UT — which companies pay providers there.
